Institute for Myeloma & Bone Cancer Research

07/09/2026

Check out: "Empowered Patient Podcast" with Karen Jagoda interviewing Debra Berenson about her books to help myeloma patients and their caregivers. ? ?

Guidance for Myeloma Patients and Caregivers with Debra Berenson Institute for Myeloma & Bone Cancer Research on the Empowered Patient Podcast with Karen Jagoda
http://empoweredpatientradio.com/guidance-for-myeloma-patients-and-caregivers-with-debra-berenson-institute-for-myeloma-bone-cancer-research

Guidance for Myeloma Patients and Caregivers with Debra Berenson Institute for Myeloma & Bone Cancer Research on the Empowered Patient Podcast with Karen Jagoda TRANSCRIPT
http://empoweredpatientradio.com/guidance-for-myeloma-patients-and-caregivers-with-debra-berenson-institute-for-myeloma-bone-cancer-research-transcript

Debra Berenson is Chair of the Fundraising Committee at the Institute for Myeloma & Bone Cancer Research and author of two books- I Have WHAT and You Have WHAT, based on her personal experience and the expertise of her husband, Dr. Jim Berenson, a myeloma expert. Multiple myeloma and related bon...

07/04/2026

250 years for America! 🎉Happy and Safe July 4th. 🇺🇸

06/21/2026

The scientists at the Institute for Myeloma & Bone Cancer Research wish you and yours a great day. 

06/03/2026

Join Dr. James Berenson's Substack.

Case A 68 year old white male with IgA lambda multiple myeloma has had an excellent response to the combination of Empliciti, Pomalyst 2 mg 21/7, and IV dexamethasone 12 mg every other week.

05/29/2026

Today is World Blood Cancer Day. Research is being conducted everyday to help you.

05/29/2026

Wishing you a meaningful Memorial Day. We pause to honor our heroes and reflect as we remember them.

05/24/2026

Your dedicated scientists from IMBCR wish you and yours a Happy Memorial Day!
"Clinical Pearls" by Dr. James R. Berenson

A 90 year-old white female with Waldenstrom’s macroglobulinemia who has been on Velcade and steroid maintenance therapy for 5 years after responding to initial treatment with Doxil, Velcade, and dexamethasone induction therapy.

05/22/2026

Clinical Pearls from May 19, 2026, James R. Berenson, MD
BerensonCancerCenter.com
A 49 year-old white female with a history of smoldering myeloma with rising IgG, M-protein, and worsening anemia for the past 3 years who has refused to start treatment for her myeloma. The patient showed iron deficiency anemia in July 2025, and she received Feraheme without significant improvement in her hemoglobin. Last month, her IgG rose to 6756, M-protein to 6.03, and serum free light chain to 314.7. Her blood counts showed her hemoglobin to be 9.6, WBC count 5.7, neutrophil count of 2.88, and platelet count of 210K.

05/20/2026

Dr. James R. Berenson shares insights about taking care of myeloma patients. BerensonCancerCenter.com https://open.substack.com/pub/jamesrberenson/p/clinical-pearls-from-may-18-2026?r=15j6j&utm_campaign=post-expanded-share&utm_medium=web

51 year old white female being treated with the bispecific antibody (BsAb) Lynozyfic which targets the B-cell maturation antigen and T-cells.

05/18/2026

Join Dr. James Berenson's Substack. His "Clinical Pearls" are enlightening. 

An 88 year-old white male with IgG kappa multiple myeloma with an 11;14 translocation has responded to treatment with Sarclisa, low dose (200 mg) venetoclax, and steroids after failing and not tolerating both Dara/Revlimid/Dex and Dara/Velcade/Dex.